Entera Bio (NASDAQ:ENTX – Get Free Report) and Tenax Therapeutics (NASDAQ:TENX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.
Analyst Ratings
This is a summary of recent ratings and target prices for Entera Bio and Tenax Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entera Bio | 1 | 0 | 0 | 1 | 2.50 |
| Tenax Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
Entera Bio presently has a consensus price target of $10.00, indicating a potential upside of 284.62%. Tenax Therapeutics has a consensus price target of $18.00, indicating a potential upside of 134.38%. Given Entera Bio’s higher probable upside, equities analysts clearly believe Entera Bio is more favorable than Tenax Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entera Bio | $180,000.00 | 662.42 | -$9.54 million | ($0.25) | -10.40 |
| Tenax Therapeutics | N/A | N/A | -$17.60 million | ($1.13) | -6.80 |
Entera Bio has higher revenue and earnings than Tenax Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Entera Bio has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Insider and Institutional Ownership
14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by company insiders. Comparatively, 3.1% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Entera Bio and Tenax Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entera Bio | -4,525.11% | -67.56% | -59.50% |
| Tenax Therapeutics | N/A | -31.34% | -30.39% |
Summary
Entera Bio beats Tenax Therapeutics on 8 of the 13 factors compared between the two stocks.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
About Tenax Therapeutics
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
